Response | OR | 95% CI | P value |
Total cohort* (n=287) | |||
SMG (high vs low) | 0.90 | 0.36 to 2.28 | 0.83 |
TATI (medium vs low) | 1.24 | 0.48 to 3.22 | 0.66 |
TATI (high vs low) | 0.39 | 0.15 to 1.02 | 0.06 |
Male† (n=184) | |||
SMG (high vs low) | 1.56 | 0.42 to 5.85 | 0.51 |
TATI (medium vs low) | 2.05 | 0.50 to 8.37 | 0.32 |
TATI (high vs low) | 0.92 | 0.22 to 3.91 | 0.91 |
Female† (n=103) | |||
SMG (high vs low) | 0.72 | 0.15 to 3.48 | 0.68 |
TATI (medium vs low) | 0.81 | 0.20 to 3.25 | 0.76 |
TATI (high vs low) | 0.19 | 0.05 to 0.77 | 0.02 |
PFS | HR | 95% CI | P value |
Total cohort* (n=287) | |||
SMG (high vs low) | 1.21 | 0.70 to 2.10 | 0.48 |
TATI (medium vs low) | 1.07 | 0.61 to 1.90 | 0.81 |
TATI (high vs low) | 1.71 | 1.01 to 2.87 | 0.04 |
Male† (n=184) | |||
SMG (high vs low) | 1.12 | 0.50 to 2.50 | 0.78 |
TATI (medium vs low) | 0.92 | 0.39 to 2.18 | 0.86 |
TATI (high vs low) | 1.40 | 0.59 to 3.31 | 0.45 |
Female† (n=103) | |||
SMG (high vs low) | 0.96 | 0.41 to 2.22 | 0.92 |
TATI (medium vs low) | 1.11 | 0.44 to 2.52 | 0.80 |
TATI (high vs low) | 2.06 | 1.06 to 3.98 | 0.03 |
OS | HR | 95% CI | P value |
Total cohort* (n=287) | |||
SMG (high vs low) | 0.99 | 0.53 to 1.83 | 0.97 |
TATI (medium vs low) | 1.18 | 0.61 to 2.26 | 0.62 |
TATI (high vs low) | 1.44 | 0.80 to 2.61 | 0.22 |
Male† (n=184) | |||
SMG (high vs low) | 0.85 | 0.36 to 2.01 | 0.71 |
TATI (medium vs low) | 0.88 | 0.35 to 2.20 | 0.78 |
TATI (high vs low) | 1.43 | 0.57 to 3.56 | 0.45 |
Female† (n=103) | |||
SMG (high vs low) | 0.83 | 0.31 to 2.21 | 0.71 |
TATI (medium vs low) | 1.80 | 0.69 to 4.68 | 0.23 |
TATI (high vs low) | 1.53 | 0.68 to 3.43 | 0.30 |
P values ≦0.05 are displayed in bold.
*Adjusted for age, sex, stage, prior treatment and SMG:TATI interaction term.
†Adjusted for age, stage, prior treatment and SMG:TATI interaction term.
OS, overall survival; PFS, progression-free survival; SMD, skeletal muscle density; SMG, skeletal muscle gauge; SMI, skeletal muscle index; TATI, total adipose tissue index.